Cabergoline is used in the treatment of hyperprolactinemic disorders due to prolactinoma (prolactin-secreting adenomas) or idiopathic hyperprolactinemia. The drug suppresses prolactin secretion, restores gonadal function, and reduces the size of prolactinomas.
Cabergoline is at least as effective as bromocriptine in normalizing serum prolactin concentrations and restoring gonadal function in women with hyperprolactinemic amenorrhea. Fewer adverse effects, especially adverse GI effects, were reported in cabergoline-treated women than in bromocriptine-treated women. Bromocriptine is preferred when restoration of fertility is the goal of therapy; this recommendation is based on the safety record of bromocriptine in pregnant women.
Cabergoline has been used for the symptomatic management of parkinsonian syndrome.
Cabergoline has been used as monotherapy for the initial symptomatic management of parkinsonian syndrome. Most clinicians would use levodopa for initial therapy in individuals >70 years of age (less likely than younger individuals to develop levodopa-related motor complications and because of concerns about cognitive dysfunction), in patients with cognitive impairment, and in those with severe disease. A dopamine receptor agonist may be preferred for initial therapy in patients 70 years of age or younger.
Cabergoline has been used as an adjunct to levodopa for the symptomatic management of parkinsonian syndrome in patients with advanced disease.